In triple-negative breast cancer (TNBC) cell lines, SP1 is an activator of acyl-CoA synthetase 4 (ACSL4), which catalyzes the conversion of fatty acids to their active acyl-CoA form. Here, ACSL4 is linked to triple-negative breast carcinoma.